A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours (NCT06725758)

🧪 Interventions in This Study

• ODM-212 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (20 Sites)

• Valkyrie Clinical Trials — Los Angeles, California
• UC Irvine Health — Orange, California
• Siteman Cancer Center — St Louis, Missouri
• Memorial Sloan Kettering Cancer Center — New York, New York
• Westchester Medical Center — Valhalla, New York
• Jefferson University Hospital — Philadelphia, Pennsylvania
• University of Texas, MD Anderson Cancer Center — Houston, Texas
• NEXT Virginia — Fairfax, Virginia
• Helsinki university Hospital — Helsinki,
• Oulu University Hospital — Oulu,
• Turku University Hospital — Turku,
• Institut Bergonie — Bordeaux,
• Centre Oscar Lambret — Lille,
• Institut Gustave Roussy — Villejuif,
• Hospital 12 de Octubre — Madrid,
• Hospital Virgen De La Macarena — Seville,
• Istituto Oncologico, Ospedale Bellinzona e Valli — Bellinzona, Canton Ticino
• Leicester Royal Infirmary — Leicester,
• Royal Marsden Hospital, London, UK — London,
• Weston Park Hospital — Sheffield,

📞 Contact the Study Coordinator

Phone: +358104261

Email: clinicaltrials@orionpharma.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Solid Tumours

• A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine — Beverly Hills, California
• Study of AZD4956 as Monotherapy and in Combination With Anti-Cancer Agents in Participants With Advanced/Metastatic Homologous Recombination Deficient Solid Tumours — New York, New York
• A Study of BI 3810944 in Patients With Advanced Cancer — Louisville, Kentucky
• A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors — Irvine, California
• A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors — Beverly Hills, California
• Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations — Anchorage, Alaska

Explore by condition: All Solid Tumours clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.